Tokushima, Japan

Hiroshi Okazaki

This inventor holds 1 USPTO granted patent. Top assignee: Otsuka Pharmaceutical Company, Limited. Active years: 1991.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hiroshi Okazaki. Retrieved from https://idiyas.com/inventor/hiroshi-okazaki-ohpabml7

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 30(Granted Patents)


Company Filing History:


Years Active: 1991

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Hiroshi Okazaki: Innovator in Nerve Cell Repair

Introduction

Hiroshi Okazaki is a notable inventor based in Tokushima, Japan. He has made significant contributions to the field of nerve cell repair through his innovative research and development.

Latest Patents

Hiroshi Okazaki holds a patent for a biphenyl derivative composition aimed at repairing nerve cell degeneration. The patent describes a biphenyl derivative of a specific formula, which includes various defined components. This composition serves as a repairing or protecting agent for nerve cells, showcasing Okazaki's commitment to advancing medical science.

Career Highlights

Okazaki is associated with Otsuka Pharmaceutical Company, Limited, where he applies his expertise in pharmaceutical research. His work focuses on developing solutions that address critical health issues related to nerve cell degeneration.

Collaborations

Throughout his career, Hiroshi Okazaki has collaborated with esteemed colleagues, including Yoji Sakurai and Takashi Hasegawa. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.

Conclusion

Hiroshi Okazaki's contributions to the field of nerve cell repair through his patented innovations highlight his role as a leading inventor in the pharmaceutical industry. His work continues to inspire advancements in medical research and treatment options.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…